Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
Status:
Completed
Trial end date:
1999-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of the buprenorphine
transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects
with osteoarthritis pain. The double-blind treatment intervention duration is 28 days.